ArticleFrontiers in public health2024
Burden of melanoma in China and its provinces from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021.
Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A comparative analysis of clinical and sonographic features: cutaneous melanoma and melanocytic nevi.Translational cancer research · 2026Article
- Clinical and Pathological Predictors of Unfavourable Outcomes in Thin and In Situ Melanomas: A Retrospective Cohort Study from Taiwan.Acta dermato-venereologica · 2026Article
- Metabolic reprogramming-a breakthrough point in overcoming resistance to BRAF mutant melanoma targeted therapy (Review).Oncology letters · 2026Review
- MSF-VMDNet for multi class segmentation of skin cancer whole slide images using a multi frequency dual encoder network.Scientific reports · 2026Article
- Clinicopathological characteristics and prognosis of melanoma: A retrospective cohort study in Xinjiang, China.PloS one · 2026Article
- Diverging Incidence and Mortality of Cutaneous Melanoma in Mainland China, 1990-2023, with Projections to 2030: A Global Burden of Disease 2023 Analysis.Clinical, cosmetic and investigational dermatology · 2026Article
- Challenges in the Diagnosis and Management of Nail Melanocytic Disorders.Clinical, cosmetic and investigational dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of melanoma in China has been increasing over the past few decades. This study aimed to investigate the burden of melanoma at both national and subnational level in China, where the population is rapidly aging. Methods: The annual melanoma data from 1990 to 2021 was collected from the Global Burden of Disease (GBD) 2021 China subnational study. Number of cases and age-standardized rates were estimated for incidence, mortality, prevalence, disability-adjusted life-years (DALYs) of melanoma by age and sex at subnational level with 33 province-level administrative units. Joinpoint regression model was used to evaluate the trends in disease burdens attributable to melanoma across time. A decomposition method was used to attribute changes in total deaths and DALYs to three explanatory components: population growth, population aging, and change of age-specific rates. Results: Over the past 30 years, the age-standardized incidence rate (ASIR) of melanoma in China has shown an upward trend. The ASIR of melanoma in 2021 was 0.7 per 100,000 (95%UI 0.4-0.9), representing an increase of 89.2% (95% UI: 14.7-157.9%) from 1990. Among younger adults aged <60 years, melanoma was more common in men, whereas among older adults who were aged >60 years, it was more common in women. The ASIR was higher in the coastal provinces in 2021 and the age-standardized rates (ASR) of DALYs was generally higher in the western provinces. Total numbers of death and DALYs of melanoma increased over the study period, mainly driven by population aging in China. Conclusion: China has experienced a substantial increase in the burden of melanoma from 1990 to 2021. It is beneficial to develop more targeted strategies for older adults populations, especially for women, to reduce the melanoma burden throughout China, particularly in some coastal and western provinces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.